Stephanie Lheureux

Dr. Stephanie Lheureux, Ph.D, M.D

Assistant Professor, University of Toronto, Toronto


Dr. Lheureux obtained her MD in Medical Oncology and PhD in translational research from France and moved to Toronto for a Clinical Research Fellowship to focus on Gynecological Cancers and Drug Development. She is Site Lead, Gynecologic Oncology and Clinician Investigator at Princess Margaret Cancer Centre (PM) and holds an Assistant Professor position in the Faculty of Medicine, at the University of Toronto. She serves as co-Chair of the NCI Cervical Task Force on Clinical Trials and have served as a member of the Steering Committee on Uterine Cancers. She is Principal Investigator of several international studies and involved in the development of early phase clinical trials with an emphasis on drug development and translational research in gynecologic malignancies.

Her academic interest is the design and development of early phase clinical trials of targeted agents in gynecologic cancers that incorporate translational endpoints and quality of life measures. This includes but is not limited to examination of chemoprevention approaches, targeted or precision therapies, immune-oncology agents, as well as leading improvements in quality of advanced cancer care. Academically, these interests have included interrogating extreme outliers of response and resistance across the disease continuum as a means of identifying predictors of therapeutic response. In particular, deep analysis of BRCA1/2 mutations in gynecologic cancers of high grade serous histology. In the last five years, she has >40 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians (IF=244), Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet Oncology and Gynecology Oncology. She is PI or co-PI in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Ontario Institute for Cancer Research and Terry Fox Research Institute that converge preclinical and clinical areas of interest and benefit from her unique expertise in each of these domains.

Funded Projects

Development of deep learning tools for deciphering intra-tumoral heterogeneity and predicting drug response in High Grade Serous Ovarian Cancer »

Research Specialties

Research Interests

  • Molecular Pathology

Contact for Collaboration

University of Toronto
Toronto, ON
Pathologists and Researchers who are interested in being part of the OMPRN: